Description

Book Synopsis
The Food and Drug Administration (FDA) oversees the safety and effectiveness of drugs sold on the U.S. market. When there is an unmet need for the treatment of a serious condition, FDA may use one or more of its expedited programs, such as fast track and breakthrough therapy designation, which are intended to bring drugs to market more quickly. FDA is also responsible for monitoring the safety of drugs and reporting on those efforts. This book examines the number and types of requests for fast track or breakthrough therapy designation; the number and types of FDA-approved drug applications that used an expedited program; and the extent to which FDAs data on tracked safety issues and postmarket studies allowed the agency to meet its reporting and oversight responsibilities.

FDA's Expedited Drug Programs: Analysis,

    Product form

    £92.79

    Includes FREE delivery

    RRP £115.99 – you save £23.20 (20%)

    Order before 4pm tomorrow for delivery by Mon 29 Jun 2026.

    A Paperback / softback by Gary Lawrence

    1 in stock

      Trusted by thousands of customers. See 2,385+ Customer Reviews

      View other formats and editions of FDA's Expedited Drug Programs: Analysis, by Gary Lawrence

      Publisher: Nova Science Publishers Inc
      Publication Date: 01/09/2016
      ISBN13: 9781634857727, 978-1634857727
      ISBN10: 1634857720
      Also in:
      Pharmacology

      Description

      Book Synopsis
      The Food and Drug Administration (FDA) oversees the safety and effectiveness of drugs sold on the U.S. market. When there is an unmet need for the treatment of a serious condition, FDA may use one or more of its expedited programs, such as fast track and breakthrough therapy designation, which are intended to bring drugs to market more quickly. FDA is also responsible for monitoring the safety of drugs and reporting on those efforts. This book examines the number and types of requests for fast track or breakthrough therapy designation; the number and types of FDA-approved drug applications that used an expedited program; and the extent to which FDAs data on tracked safety issues and postmarket studies allowed the agency to meet its reporting and oversight responsibilities.

      Recently viewed products

      © 2026 Book Curl

        • American Express
        • Apple Pay
        • Diners Club
        • Discover
        • Google Pay
        • Maestro
        • Mastercard
        • PayPal
        • Shop Pay
        • Union Pay
        • Visa

        Login

        Forgot your password?

        Don't have an account yet?
        Create account